The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential

Background: Clinical management of ischemic events and prevention of vascular disease is based on antiplatelet drugs. Given the relevance of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) as a candidate target in thrombosis, the main goal of the present study was to identify novel antiplatele...

Full description

Bibliographic Details
Main Authors: María N. Barrachina, Irene Izquierdo, Lidia Hermida-Nogueira, Luis A. Morán, Amparo Pérez, Ana B. Arroyo, Nuria García-Barberá, Rocío González-Conejero, Sara Troitiño, Johannes A. Eble, José Rivera, Constantino Martínez, María I. Loza, Eduardo Domínguez, Ángel García
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
platelets
Idelalisib
PI3K inhibitors
Online Access:https://www.mdpi.com/1422-0067/22/7/3304

Internet

https://www.mdpi.com/1422-0067/22/7/3304

Similar Items